TERAZOL 3
LOE ApproachingNDAVAGINALCREAM
Approved
Feb 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 3 is a vaginal antifungal cream approved in 1991 for the treatment of vulvovaginal candidiasis. The product is a small-molecule therapeutic administered topically as a 3-day regimen. It represents a mature, established treatment option in the vaginal antifungal category.
LOE Approaching
Product is in mature stage with approaching loss of exclusivity; commercial team likely focused on brand loyalty and market defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity; roles on this product are likely backfill or transition-focused rather than growth-oriented. Career progression may be limited unless you are managing LOE strategy or defending market share during competitive erosion.
Brand ManagerField Sales Representative
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.